BR112023017746A2 - Terapia para câncer envolvendo células t projetadas com cars e parvovírus h-1 - Google Patents
Terapia para câncer envolvendo células t projetadas com cars e parvovírus h-1Info
- Publication number
- BR112023017746A2 BR112023017746A2 BR112023017746A BR112023017746A BR112023017746A2 BR 112023017746 A2 BR112023017746 A2 BR 112023017746A2 BR 112023017746 A BR112023017746 A BR 112023017746A BR 112023017746 A BR112023017746 A BR 112023017746A BR 112023017746 A2 BR112023017746 A2 BR 112023017746A2
- Authority
- BR
- Brazil
- Prior art keywords
- parvovirus
- cells
- cancer
- engineered
- cancer therapy
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title abstract 4
- 241000702620 H-1 parvovirus Species 0.000 title abstract 3
- 238000011275 oncology therapy Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 238000002659 cell therapy Methods 0.000 abstract 3
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 abstract 1
- 230000003044 adaptive effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 201000005787 hematologic cancer Diseases 0.000 abstract 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 244000309459 oncolytic virus Species 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/46448—Cancer antigens from embryonic or fetal origin
- A61K39/464482—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/11—Antigen recognition domain
- A61K2239/15—Non-antibody based
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
- A61K2239/29—Multispecific CARs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/50—Cell markers; Cell surface determinants
- C12N2501/515—CD3, T-cell receptor complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
terapia para câncer envolvendo células t projetadas com cars e parvovírus h-1. a presente invenção refere-se a composições, métodos, usos e kits para terapias combinadas envolvendo imunoterapias, tais como terapia celular adaptativa, por exemplo, terapia com células t, e um vírus oncolítico (particularmente parvovírus h-1), para tratamento de indivíduos com câncer. a terapia com células t inclui células que expressam receptores recombinantes, tais como receptores de antígenos quiméricos (cars). em algumas modalidades, o câncer é um tumor sólido ou uma malignidade hematológica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21160732.0A EP4052716A1 (en) | 2021-03-04 | 2021-03-04 | Cancer therapy involving car-engineered t-cells and parvovirus h-1 |
| PCT/EP2022/055394 WO2022184824A2 (en) | 2021-03-04 | 2022-03-03 | Cancer therapy involving car-engineered t-cells and parvovirus h-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023017746A2 true BR112023017746A2 (pt) | 2023-10-03 |
Family
ID=75172984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023017746A BR112023017746A2 (pt) | 2021-03-04 | 2022-03-03 | Terapia para câncer envolvendo células t projetadas com cars e parvovírus h-1 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240075085A1 (pt) |
| EP (2) | EP4052716A1 (pt) |
| JP (1) | JP2024519428A (pt) |
| KR (1) | KR20230155502A (pt) |
| CN (1) | CN116981465A (pt) |
| AU (1) | AU2022230739A1 (pt) |
| BR (1) | BR112023017746A2 (pt) |
| CA (1) | CA3213301A1 (pt) |
| CL (1) | CL2023002591A1 (pt) |
| IL (1) | IL305503A (pt) |
| MX (1) | MX2023010308A (pt) |
| WO (1) | WO2022184824A2 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015013737B1 (pt) | 2012-12-13 | 2021-07-27 | Ruprecht-Karls-Universitãt Heidelberg | Peptídeos com alteração do quadro de leitura msiespecífico (fsp) para a prevenção e tratamento do câncer |
| US20180289689A1 (en) | 2014-10-27 | 2018-10-11 | Ruprecht-Karls-Universität Heidelberg | Use of ccr5 antagonists alone or in combination therapy for the treatment of cancer |
-
2021
- 2021-03-04 EP EP21160732.0A patent/EP4052716A1/en not_active Ceased
-
2022
- 2022-03-03 JP JP2023553471A patent/JP2024519428A/ja active Pending
- 2022-03-03 WO PCT/EP2022/055394 patent/WO2022184824A2/en active Application Filing
- 2022-03-03 KR KR1020237033723A patent/KR20230155502A/ko unknown
- 2022-03-03 CA CA3213301A patent/CA3213301A1/en active Pending
- 2022-03-03 IL IL305503A patent/IL305503A/en unknown
- 2022-03-03 BR BR112023017746A patent/BR112023017746A2/pt unknown
- 2022-03-03 AU AU2022230739A patent/AU2022230739A1/en active Pending
- 2022-03-03 CN CN202280018306.2A patent/CN116981465A/zh active Pending
- 2022-03-03 EP EP22713358.4A patent/EP4301379A2/en active Pending
- 2022-03-03 MX MX2023010308A patent/MX2023010308A/es unknown
-
2023
- 2023-08-31 CL CL2023002591A patent/CL2023002591A1/es unknown
- 2023-09-01 US US18/459,879 patent/US20240075085A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116981465A (zh) | 2023-10-31 |
| CL2023002591A1 (es) | 2024-01-26 |
| WO2022184824A3 (en) | 2022-11-24 |
| WO2022184824A2 (en) | 2022-09-09 |
| KR20230155502A (ko) | 2023-11-10 |
| IL305503A (en) | 2023-10-01 |
| CA3213301A1 (en) | 2022-09-09 |
| JP2024519428A (ja) | 2024-05-14 |
| MX2023010308A (es) | 2023-12-15 |
| EP4052716A1 (en) | 2022-09-07 |
| EP4301379A2 (en) | 2024-01-10 |
| AU2022230739A1 (en) | 2023-09-14 |
| US20240075085A1 (en) | 2024-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017010190A2 (es) | Terapias cd20, terapias cd22 y terapias de combinación con una célula que expresa un receptor quimérico de antígeno (car) de cd19 | |
| BR112019006781A2 (pt) | receptores de antígeno quiméricos para o tratamento de câncer | |
| BR112020012647A8 (pt) | Anticorpos anti-tígitos e seu uso como agentes terapêu-ticos e diagnósticos | |
| BR112018070676A2 (pt) | construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos | |
| BR112018076306A2 (pt) | composições e métodos para a supressão de células cd117+ | |
| BR112016016699A2 (pt) | Anticorpos humanos para pd-1 | |
| BR112018009098A8 (pt) | métodos e composições para edição genética em células-tronco hematopoiéticas | |
| BR112017022249A2 (pt) | células t gama delta modificadas e usos destas | |
| BR112018069075A2 (pt) | métodos e composições para transduzir linfócitos e expansão regulada dos mesmos | |
| BR112018076263A2 (pt) | composições e métodos para a depleção de células | |
| BR112015007184A2 (pt) | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer | |
| BR112017019914A2 (pt) | receptores de antígenos quiméricos direcionados para antígeno de amadurecimento de células b | |
| BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
| BR112021024822A2 (pt) | Terapia de combinação de terapia citotóxica mediada por células e inibidor de proteína da família bcl2 pró-sobrevivência | |
| UY28028A1 (es) | Anticuerpos que enlazan a células asociadas ca 125/0772p y metodos de uso derivados | |
| AR117685A1 (es) | Antígeno quimérico y receptores de células t y métodos de uso | |
| BR112021021843A2 (pt) | Composições de proteína de fusão quimicamente projetada e métodos de uso das mesmas | |
| CO2021010347A2 (es) | Células modificadas por receptor de antígeno quimérico para el tratamiento de cánceres que expresan cldn6 | |
| BR112014026740A2 (pt) | anticorpo, composição, métodos para tratar um mamífero e para fornecer um anticorpo com adcc realçada, e, uso de um anticorpo | |
| BR112022010627A2 (pt) | Anticorpos anti-idiotípicos para domínios de ligação alvejados por bcma e composições e métodos relacionados | |
| CL2009000567A1 (es) | Anticuerpo monoclonal que enlaza especificamente tyrp1 humano; fragmento de cualquiera de los anticuerpos antes indicado; acido nucleico que codifica en anticuerpo o fragmento; vector de expresion; celula recombinante; uso del anticuerpo o fragmento para tratar cancer. | |
| BR112021021608A2 (pt) | Células car-t direcionadas a cd19 específicas para antígeno | |
| BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
| BR112021021542A2 (pt) | Terapia celular alogênica de malignidades de células b com o uso de células t geneticamente modificadas que têm como alvo cd19 | |
| JOP20220018A1 (ar) | مستقبل المستضدات الخيمري لـ hK2 المضاد (CAR) |